Premium
Inositol may worsin attention deficit disorder with hyperactivity
Author(s) -
Levine Joseph,
Ring Aliza,
Barak Yoram,
Elizur Avner,
Belmaker R. H.
Publication year - 1995
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.470100608
Subject(s) - inositol , placebo , phosphatidylinositol , antidepressant , second messenger system , depression (economics) , placebo controlled study , endocrinology , medicine , pharmacology , receptor , psychology , chemistry , double blind , biochemistry , kinase , pathology , alternative medicine , hippocampus , economics , macroeconomics
Antidepressant drugs have been reported to improve ADDH symtomatology. Myoinositol is a simple isomer of glucose and is the precursor of the phosphatidylinositol second messenger system in brain. Both α 1 ‐adrenergic and 5HT 2 receptors activate this second messenger system. Recently, we found inositol to be effective in depression. Therefore we decided to evaluate the effects of oral inositol in children with ADDH in a double‐blind, cross‐over, placebo‐controlled manner. Eleven children, mean age 8.9 ± 3.6 years with a mean illness duration of 4.5 ± 2.8 years were enrolled in an 8‐week trial. Inositol or dextrose (placebo) was dispensed in powder form at a dose of 200 mg/kg aggravation of the syndrome with myo‐inositol as compared to placebo.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom